Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

Existing cancer drug SAHA may protect the heart during chemotherapy

Sep 21, 2026 September 21, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

Researchers at Heidelberg University have identified how the chemotherapy drug doxorubicin damages the heart and found that SAHA, an existing cancer drug, can mitigate this damage. This discovery could enhance cancer treatment protocols, potentially benefiting Iranian patients undergoing chemotherapy. The findings highlight advancements in cancer treatment that may influence healthcare strategies in Iran.

🔍 Quick Context Guide
💡 Bottom Line: The discovery of SAHA's protective effects could significantly improve the safety of chemotherapy for cancer patients.

👥 Key Players

Heidelberg Faculty of Medicine MENTIONED
Research institution
"Their research contributes to advancements in cancer treatment, which can directly impact patient care in Iran."
SAHA (suberoylanilide hydroxamic acid) MENTIONED
Existing cancer drug
"As a potential protective agent against chemotherapy side effects, it may improve treatment outcomes for Iranian cancer patients."

📰 What Happened

Researchers discovered how doxorubicin damages the heart during chemotherapy and found that SAHA can mitigate this damage. This could lead to improved cancer treatment protocols.

  • Doxorubicin is an effective chemotherapy drug but can harm the heart.
  • SAHA has shown promise in protecting heart muscle cells in studies.

💡 Why It Matters

🇮🇷 For Iran: Improved cancer treatment protocols could enhance patient outcomes in Iran, where cancer treatment is a critical health issue.
🌍 Regional: Advancements in cancer treatment can set a precedent for other countries in the region facing similar healthcare challenges.
🌐 International: This research may influence global cancer treatment strategies and drug use, potentially affecting pharmaceutical markets.

📚 Background

Doxorubicin is widely used in chemotherapy but has known cardiotoxic effects. Research into mitigating these effects is crucial for improving patient care.

Chemotherapy Cardiotoxicity in cancer treatment
📡 Source: NEUTRAL
📊 Confidence: 70%
The findings are based on scientific research and are presented without apparent bias.

The chemotherapy agent doxorubicin is used successfully to treat a range of cancers but can, as a side effect, damage the heart muscle. Researchers at the Heidelberg Faculty of Medicine at Heidelberg University have now identified the molecular signaling pathway through which doxorubicin causes cardiac injury. They also discovered that SAHA (suberoylanilide hydroxamic acid), a drug already approved for the treatment of certain cancers, attenuated harmful mechanisms in heart muscle cells in cell-based and animal studies and could therefore help protect the heart.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →